Utility of NT-proBNP for diagnosing heart failure in a heterogeneous population of patients with dyspnea. Spanish multicenter study;Utilidad del NT-proBNP para el diagnóstico de insuficiencia cardiaca en una población heterogénea de pacientes con disnea. Estudio multicéntrico español

Revista Espanola de Cardiologia

Volumn 59, Issue 5, 2006, Pages 465-472

  Anguita, Manuel ^a,m   Montes, Pedro ^b   Jordán, Alejandro ^c   Casares, Gerardo ^d   Gómez, Inés ^e   Recio, Jesús ^f   Martínez, Ángel ^g   Zumalde, Javier ^h   Povar, Javier ⁱ   Ridocci, Francisco ^j   Roig, Eulalia ^k   Batlle, Elena ^l   Eguia I ^b   Rueda, I ^b   Garcia de Burgo F ^c   Lujan J ^c   Sanchez J F ^c   Ojeda, S ^a   Aguilera, C ^a   Perez T ^a   Fernandez I ^d   Fernandez A ^d   Ventas, R ^d   Lopez D ^e   Soto, F ^e   Ruiz, E ^f   Alegre, J ^f   Segura, R ^f   Sevillano, C ^g   Fatela, D ^g   Izquierdo, F ^h   Lecuona, I ^h   Franco, J M ⁱ   Sanz, M ⁱ   Garcia de Jalon A ⁱ   Federico, P ^j   Manzo V ^j   Marin J L ^k   Miro O ^k   Espana E ^l   Jimenez J ^l   more..

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL SAN AGUSTÍN   (Spain)

^e University Hospital of Santiago de Compostela   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL DE GALDAKAO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^m Hospital de Cruces ^*  (Spain)

more..

Author keywords

Diagnosis; Heart failure; Natriuretic peptides; NT proBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DYSPNEA; FEMALE; HEART FAILURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPAIN; STATISTICAL SIGNIFICANCE;

EID: 33745325682     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087899     Document Type: Article

References (26)

1. Anguita M. Diagnóstico y tratamiento de la insuficiencia cardiaca diastólica. Rev Esp Cardiol. 2004;57:570-5.
2. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-40.
3. Hobbs FD, Jones MI, Allan TE, Wilson S, Tobias R. European survey of primary care physicians perceptions on heart failure diagnosis and management. Eur Heart J. 2000;21:1877-87.
4. Roig E. Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardiaca. Rev Esp Cardiol. 2004;57:347-56.
5. Anguita M. Marcadores bioquímicos en la insuficiencia cardiaca: ¿todos iguales? Rev Esp Cardiol. 2005;58:239-41.
6. Bayés-Genís A, Santaló M, Zapico E, López L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301-8.
7. Bay M, Kirk J, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart. 2003;89:150-4.
8. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrandt P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail. 2004;6:269-74.
9. Nielsen OW, Kirk V, Bay M, Boesgaard S, Nielsen H. Value of N-terminal probrain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study. Eur J Heart Fail. 2004;6:275-80.
10. De Lemos J, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316-22.
11. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728-35.
12. Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 2002;143:923-9.
13. Gardner RS, Ozalp F, Murday AJ, Robb D, McDonagh TA. N-terminal pro brain natriuretic peptides. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735-43.
14. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal pro brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-74.
15. Gardner RS, Chong V, Morton I, McDonagh TA. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumor necrosis factor-alfa in patients referred for consideration of cardiac transplantation. Eur J Heart Fail. 2005;7:253-60.
16. Richards M, Throughton RW. NT-pro BNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail. 2004;6:351-4.
17. Ambrosi A, Oddoze C, Riberi A, Arques S, Portugal H, Metras D, et al. Usefulness of N-terminal pro brain natriuretic peptide levels in predicting survival in heart transplant recipients. Am J Cardiol. 2004;94:1585-7.
18. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Aemstrong P, et al. N-terminal pro brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation. 2003;108:275-81.
19. Jernberg T, Stridsvberg M, Venge P, Lindhl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437-45.
20. Qi W, Mathisen P, Kjekshus JJ. Natriuretic peptides in patients with aortic stenosis. Am Heart J. 2001; 142:725-32.
21. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277-84.
22. Pascual DA, Cerdán MC, Noguera JA, Casas T, Muñoz L, García R, et al. Utilidad del NTproBNP en el manejo urgente del paciente con disnea severa y diagnóstico, dudoso de insuficiencia cardiaca. Rev Esp Cardiol. 2005;58:1155-61.
23. Bayés-Genís A. Nt-proBNP circulante, un nuevo biomarcador para. el diagnóstico de insuficiencia cardiaca. Rev Esp Cardiol. 2005;58:1142-4.
24. Taléns-Visconti R, Rivera M, Sánchez-Tello MJ, García de Burgos F, Martínez-Dolz L, Sevilla B, et al. Left ventricular cavity reflects N-terminal probrain natriuretic peptide plasma levels in heart failure. Eur J Echocardiography. 2006;7:45-52.
25. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayés-Genís A, Ordóñez-Llanos J, Santaló-Bel, et al. NT-proBNP testing for diagnosis and short term prognosis in acute destabilized heart failure: an international pooled analysis at 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2005; 27:330-7.
26. Rivera M, Cortés R, Salvador A, Bertoméu V, García de Burgos F, Payá R, et al. Obese subjects with heart failure have lower N-terminal probrain natriuretic peptide plasma levels irrespective of etiology. Eur J Heart Fail. 2005;7:1168-70.